Oraqix (Lidocaine, Prilocaine)

Lidocaine, the active ingredient in Oraqix, is a local anesthetic presented as a gel for intra‑oral use. It provides surface anesthesia for dental procedures and minor oral surgeries in adult patients. GNH USA supplies Oraqix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

GNH USA supplies Oraqix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Oraqix is a topical local anesthetic used in the oral cavity to provide pain control for specific dental and oral procedures.

- Periodontal surgery: Provides localized anesthesia without the need for injectable anesthetic. - Tooth extraction: Reduces discomfort during and after the procedure. - Scaling and root planing: Improves patient comfort during deep cleaning. - Oral mucosal biopsies: Facilitates painless removal of small tissue samples. - Dental implant placement: Assists in achieving adequate so‑l­ t‑  l  un‑      un  ‑  ‑  un  ‑  ‑  un‑ un ‑ un‑un‑ un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un‑un​

Oraqix may cause local and systemic reactions following application to the oral mucosa.

Common Side Effects: - Transient burning or stinging sensation at the application site. - Mild oral mucosal irritation or erythema. - Temporary numbness lasting longer than the procedure. - Taste alteration or metallic taste. - Mild headache.

Serious or Rare Side Effects: - Allergic reaction such as urticaria, angio‑edema, or anaphylaxis. - Methemoglobinemia, particularly with excessive absorption. - Cardiovascular changes including hypotension or arrhythmia. - Central nervous system toxicity presenting as seizures. - Persistent numbness beyond 24 hours.

Oraqix should be used only when the benefits outweigh potential risks, and clinicians should follow established dental protocols.

- Patient assessment: Verify no known allergy to amide‑type local anesthetics. - Dosage control: Apply only the amount required for the targeted area. - Medical history: Review for conditions that predispose to methemoglobinemia. - Concurrent medications: Use caution with other sodium‑channel blockers. - Monitoring: Observe the patient for signs of systemic toxicity during and after use. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Oraqix may interact with other medications that affect sodium channels or hemodynamic stability.

Major Interactions (Avoid): - Class  ");

Minor  

""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""""